Right Answers, Wrong Ques2ons. Ralph I Horwitz
|
|
- Hector McKinney
- 5 years ago
- Views:
Transcription
1 Right Answers, Wrong Ques2ons Ralph I Horwitz
2 Disclosures Employed by GlaxoSmithKline Views expressed reflect mine alone and not those of GSK
3 Right Answer, Wrong Ques2on A young couple moves into an apartment and decides to repaper the dining room. They ask the neighbor who has a dining room the same size, How many rolls of wallpaper did you buy when you papered your dining room? Seven, he says So the couple buys seven rolls of expensive paper, and they start papering. When they get to the end of the fourth roll, the dining room is finished. Annoyed, they go back to the neighbor and say We followed your advice, but we ended up with three extra rolls! So, he says, that happened to you too. (Cathcart and Klein. Plato and a Platypus Walk into a Bar...)
4 Right Answers, Wrong Ques2ons Emphasis on internal validity has made the quality of the answer more important than quality of ques2on When efficacy trials dominate a collateral effect is to diminish the emphasis on the pa2ent s experience with disease and treatment that are oven bewer captured in effec2veness studies
5 Right Answers, Wrong Ques2ons: Key Messages Benefits and harms may differ in studies designed for effec2veness rather than efficacy Medicines that have less efficacy in tradi2onal RCTs may be more effec2ve in real- world use Pa2ent- centered informa2on (symptoms, func2on, well- being) needs greater emphasis Observa2onal studies are a model for design and analysis of Effec2veness RCTs
6 Right Answers, Right Ques2ons For RCTs For Observa2onal studies For Pa2ents
7 Right Ques2ons for RCTs: Montelukast and Asthma Leukotriene receptor antagonist Approved to treat Asthma Popular with pa2ents and physicians
8 Efficacy Trials: Montelukast vs ICS and LABA ICS and LABA have greater improvement in lung func2on (FEV1) and airway response to inhaled methacholine, and Greater reduc2on in severe exacerba2ons
9 From: Oral Montelukast, Inhaled Beclomethasone, and Placebo for Chronic Asthma: A Randomized, Controlled Trial Ann Intern Med. 1999;130(6): doi: / Figure Legend: Mean percentage change from baseline (SE) in FEV 1 over the 12-week treatment period.nn± Black circles represent patients receiving montelukast, 10 mg once daily; black triangles represent patients receiving inhaled beclomethasone, 200 µg twice daily; and squares represent patients receiving placebo. The dotted lines represent the treatment effect for the subsets of patients switched from active treatment to placebo (according to the initial allocation schedule) during the washout period. White circles represent patients switched from montelukast to placebo ( = 52); white triangles represent patients switched from beclomethasone to placebo ( = 43). Date of download: Copyright The American College of Physicians. 5/10/2013 All rights reserved.
10 Effec2veness Trials of Montelukast Two pragma2c, open label RCTs of LTRA vs. ICS for first- line controller therapy or vs. LABA as add- on to ICS Eligible pa2ents with poor scores on Asthma Q of L or Asthma Control Ques2onnaire At 2 months and 2 years of follow up, LTRA equivalent to ICS and LABA add- on Price et al, NEJM 2011
11 Medicine with less efficacy in tradi2onal RCTs may have more effec2veness in Real World studies Why Might This Occur???
12 Less Efficacy, More Effec2veness One explana2on is greater adherence (easier to take a pill than use an inhaler) (adherence to LTRA ~65-75%; ICS ~45%) But there are others: more heterogeneous popula2on (es2mated that tradi2onal RCTs exclude 95% asthma pa2ents) role of co- medica2ons focus on pa2ent symptoms as outcomes
13 Efficacy vs. Effectiveness EFFICACY EFFECTIVENESS POPULATION Homogeneous Heterogeneous MEDICAL PROBLEM Narrow Disease Spectrum Broad Disease Spectrum CONDITIONS OF USE BENEFITS Strict Guidelines for Use of Main & Concomitant Medicines Hard Endpoints (Death, Major Morbidity) Real- World SoVer Endpoints (Func2oning, Symptoms, Pa2ent Preferences) Office of Technology Assessment, 1978
14 Key Message #1 Benefits and Harms of Medicines differ in Efficacy and Effec2veness Studies
15 Right Answer, Wrong Ques2on: For Observa2onal Studies Ques2on: What is the effect of postmenopausal hormone therapy on risk of coronary heart disease in postmenopausal women?
16 Right Answers, Wrong ques2ons: Observa2onal Studies Observa2onal studies >30% lower risk in current users compared with never users e.g., HR 0.68 in Nurses Health Study (Grodstein et al. J Women s Health 2006) Randomized trial >20% higher risk in ini2ators compared with non- ini2ators HR 1.24 in Women s Health Ini2a2ve (Manson et al. NEJM 2003)
17 Why Did Observa2onal Studies Disagree with RCTs? Common Explana2on: Residual Confounding (insufficient control for CHD, SES, lifestyle) (deficiencies in Observa2onal Studies) Another Explana2on: Asked Different Ques2ons
18 Randomized Trial: Clinically Relevant Ques2on What is CHD risk in women who ini2ate hormone treatment compared with women who ini2ate placebo or alterna2ve treatments? Design: Randomize to start hormone treatment or placebo Analysis: Compare incident (new) users and non- users
19 Observa2onal Studies: Clinically Irrelevant Ques2on What is risk of CHD in women currently taking hormone therapy compared with women who are not? Design: women who chose whether to use HRT Analysis: comparison of prevalent users of HRT vs. Never- Users (current vs. never users)
20 Current vs. Never Users Answers Irrelevant Ques2on Does not help woman wondering whether to start treatment. Does not help woman wondering whether to stop.
21 Women s Health Ini2a2ve vs. Nurses Health Study: New Users WHI NHS OVERALL YRS of F/U > (ITT Analysis) Hernan, et al
22 Ques2on MaWers More than Method RCT ques2on was clinically relevant one RCT and OS get same answer when they ask the same ques2on RESEARCH DESIGNS ARE FLAT, NOT HIERARCHICAL
23 KEY MESSAGE #2 BENEFITS AND HARMS DIFFER IN EFFICACY AND EFFECTIVENESS STUDIES QUESTION MATTERS MORE THAN METHOD
24 Right Answers, Wrong Ques2ons: For Pa2ents
25 What a Patient Wants " How will this medicine affect me? How will it make me feel bewer or be more ac2ve? How long will it take me to feel bewer or do more? " What are the poten2al harms and benefits if I take/switch to this medicine? " What is the best result I can expect? How will my adherence affect the results? What does high/low adherence look like? Can I be adherent to the regimen? " Is this treatment the best choice for me? Does it fit my lifestyle? Can I accept the risk/benefit balance? How will it impact my other diseases/ medicines?
26 Patient Centered Information: What is it? Patient Reported Outcomes (PRO) Any report of the status of a patient s health condition that comes directly from the patient, without interpretation by a clinician or anyone else. Typically a validated instrument Patient Centered Information (PCI): Clinical Dialogue Symptom Severity Daily Living Activities Physical Activity Social & Behavioral Functioning Well-Being Preferences
27 Prominent Organiza2ons Suppor2ng PCI IOM High Quality Health Care Patient-centered providing care that is respectful of and responsive to individual patient preferences, needs, and values and ensuring that patient values guide all clinical decisions Patient-Centered Outcomes Research Institute (PCORI) To help people make informed health care decisions Focusing on outcomes that people care about such as survival, function, symptoms.
28 Prominent Organiza2ons Suppor2ng PCI ASCO Draft Recommendations to Raise the Bar for Clinical Trials Focus on what is Clinically Meaningful Inspire Patients and Investigators to demand more from Clinical Trials Vote with you feet participate in trials that meet these recommendations
29 Utilization of Innovative Design & Data Collection Rigorous Qualitative Research to Identify: Patient-Centered Information Patient-Preferred Outcomes (What is most important to the patient?) Patient Centered Information Longitudinal Web-Based Data Collection Smart Phones Social media EMR (Structured Data Collection, NLP)
30 KEY MESSAGE #3 BENEFITS AND HARMS DIFFER IN EFFICACY AND EFFECTIVENESS STUDIES QUESTION MATTERS MORE THAN METHOD RESTORE PRIMACY OF PATIENT DIALOGUE IN DESIGN OF CLINICAL RESEARCH
Welcome! Pragmatic Clinical Studies. David Hickam, MD, MPH Program Director Clinical Effectiveness Research. David Hickam, MD, MPH
Pragmatic Clinical Studies David Hickam, MD, MPH Program Director Clinical Effec2veness Research June 23, 2015 Welcome! David Hickam, MD, MPH Program Director Clinical Effectiveness Research 2 In this
More informationGeneralizing the right question, which is?
Generalizing RCT results to broader populations IOM Workshop Washington, DC, April 25, 2013 Generalizing the right question, which is? Miguel A. Hernán Harvard School of Public Health Observational studies
More informationBeyond the intention-to treat effect: Per-protocol effects in randomized trials
Beyond the intention-to treat effect: Per-protocol effects in randomized trials Miguel Hernán DEPARTMENTS OF EPIDEMIOLOGY AND BIOSTATISTICS Intention-to-treat analysis (estimator) estimates intention-to-treat
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2017?
Global Initiative for Asthma (GINA) GINA Global Strategy for Asthma Management and Prevention Asthma-COPD overlap The word syndrome has been removed from the previous term asthma-copd overlap syndrome
More informationPutting NICE guidance into practice. Resource impact report: Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Putting NICE guidance into practice Resource impact report: Asthma: diagnosis, monitoring and chronic asthma management (NG80) Published: November 2017 Summary This report focuses on the recommendations
More informationInhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years & over
Manufacturer Submission To The National Institute for Health and Clinical Excellence By GlaxoSmithKline UK Inhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years
More informationCOMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH. Ross L. Prentice. Fred Hutchinson Cancer Research Center
COMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH Ross L. Prentice Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North, M3-A410, POB 19024, Seattle,
More informationLearning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
More informationState of the art pharmacoepidemiological study designs for post-approval risk assessment
State of the art pharmacoepidemiological study designs for post-approval risk assessment Cardiac Safety Research Consortium Think Tank Round Table Meeting Thursday, March 6, 2014 Jennifer L. Lund, PhD
More informationumeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline
umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationWho can get most benefit
Who can get most benefit from tiotropium in asthma? Y-M. Oh Asan Medical Center Univ. of Ulsan College of Medicine Seoul, Korea Tiotripium for Asthma 1 New in GINA 2015 Add-on tiotropium by soft-mist inhaler
More informationChemo Brain and Fa.gue Chemotherapy Related Cogni:ve Impairment Chemotherapy Related Fa:gue. Alok Pant, MD Northwestern Medicine
Chemo Brain and Fa.gue Chemotherapy Related Cogni:ve Impairment Chemotherapy Related Fa:gue Alok Pant, MD Northwestern Medicine Chemotherapy Related Cogni.ve Changes Agen:on Concentra:on Learning Memory
More informationMaking Your Treatment Work Long-Term
Making Your Treatment Work Long-Term How to keep your treatment working... and why you don t want it to fail Regardless of the particular drugs you re taking, your drugs will only work when you take them.
More informationLong Term Care Formulary RS -29
RESTRICTED USE Asthma/COPD Management 1 of 6 PROTOCOL: Asthma Glossary of Medication Acronyms: SABA: short-acting beta agonist (e.g. salbutamol) SABD: short-acting bronchodilator (e.g. ipratropium or SABA)
More informationUsing Electronic Pa0ent-Reported Outcomes to Monitor and Manage Symptoms in Cancer Care
Using Electronic Pa0ent-Reported Outcomes to Monitor and Manage Symptoms in Cancer Care Ethan Basch, MD, MSc University of North Carolina, USA June 2018 Background Symptoms are common among pa0ents with
More informationDebate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza
Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza Aeron Hurt WHO Collabora@ng Centre for Reference and Research on Influenza, Melbourne, Australia www.influenzacentre.org NA inhibitor
More informationDesign, Conduct and Analysis of Pragma?c Clinical Trials in Pallia?ve Care Research
Design, Conduct and Analysis of Pragma?c Clinical Trials in Pallia?ve Care Research Sco$ D. Halpern, M.D., Ph.D. Associate Professor of Medicine, Epidemiology, and Medical Ethics & Health Policy Director,
More informationLearning Objec1ves. Study Design Considera1ons in Clinical Pharmacy
9/28/15 Study Design Considera1ons in Clinical Pharmacy Ludmila Bakhireva, MD, PhD, MPH Pree Sarangarm, PharmD, BCPS Learning Objec1ves Describe the features, advantages and disadvantages of the observa1onal
More informationfluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK
fluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK 09 May 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationResponsible Respiratory Prescribing
Responsible Respiratory Prescribing Dr Vincent Mak Consultant Physician in Respiratory Integrated Care Imperial College Healthcare and Central London Community Healthcare NHS Trust NHS England (London)
More informationLearning Objec1ves. Study Design Strategies. Cohort Studies 9/28/15
9/28/15 Learning Objec1ves Describe the features, advantages and disadvantages of the observa1onal study designs Explain why the overall study design is important when evalua1ng studies & applying their
More informationWHI, Nurses and SWANs: Do Big Clinical Trials Inform Personalized Care? KIRTLY PARKER JONES MD
WHI, Nurses and SWANs: Do Big Clinical Trials Inform Personalized Care? KIRTLY PARKER JONES MD Conflicts? No financial conflicts of interest (Dr. Jones is a post menopausal female reproductive endocrinologist
More informationOncology Care Model Overview
Oncology Care Model Overview Centers for Medicare & Medicaid Services Innova3on Center (CMMI) September 2017 Innova3on at CMS Center for Medicare & Medicaid Innova3on (Innova3on Center) Established by
More informationPragma&c Clinical Trials
Pragma&c Clinical Trials Susanne May, PhD Associate Professor Department of Biosta&s&cs, School of Public Health, University of Washington Preliminaries PLEASE ask ques&ons at any &me REALLY good clinical
More informationThe future of ARIA guidelines
The future of ARIA guidelines Evidence- based medicine GRADE Recommenda
More informationOutcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCHILDREN S HEALTH SURVEY
CHILDREN S HEALTH SURVEY FOR ASTHMA CHILD VERSION The purpose of this survey is to find out how much asthma affects the everyday life of both you and your family. THERE ARE NO RIGHT OR WRONG ANSWERS!!
More informationCommon Data Elements: Making the Mass of NIH Measures More Useful
Common Data Elements WG Common Data Elements: Making the Mass of NIH Measures More Useful Jerry Sheehan Assistant Director for Policy Development Na?onal Library of Medicine Gene/c Alliance Webinar Series
More informationExpert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Full Report 2007
Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma Full Report 2007 TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS Selecting Initial Therapy
More informationMedication Adherence Campaign Target Market Tracking Survey Results National Consumers League October 9, 2015
Medication Adherence Campaign Target Market Tracking Survey Results National Consumers League October 9, 2015 Objectives An ini%al target market survey was launched in May 2011 to serve as a benchmark
More informationGreater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma
Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Non-pharmacological options for ALL patients, consider at ALL stages Make sure diagnosis
More informationInterventions to improve adherence to inhaled steroids for asthma. Respiratory department
Interventions to improve adherence to inhaled steroids for asthma Respiratory department Content Overview Research References Overview Asthma is a chronic breathing condition that affects more than 300
More informationBreast Cancer Update Michael B. Peyser MS MD FACS Fellow Society of Surgical Oncology Windsong Breast Care
Breast Cancer Update 2017 Michael B. Peyser MS MD FACS Fellow Society of Surgical Oncology Windsong Breast Care Used with permission by Anna Chen MD, Windsong Radiology Group Statistics as of 2013 230,815
More informationA primary care perspective on the new British asthma guideline
A primary care perspective on the new British asthma guideline Bronwen Thompson discusses the revisions to the BTS/SIGN guideline with Dr Hilary innock This guideline update 1 is significant. It builds
More informationResponsible Respiratory Prescribing
Responsible Respiratory Prescribing Dr Vincent Mak Consultant Physician in Respiratory Integrated Care Imperial College Healthcare and Central London Community Healthcare NHS Trust NHS England (London)
More informationScottish Medicines Consortium
Scottish Medicines Consortium montelukast 10mg tablets (Singulair ) No. (185/05) Merck, Sharp & Dohme Ltd (MSD) New indication: for asthmatic patients in whom montelukast is indicated in asthma, montelukast
More informationBiosta's'cs Board Review. Parul Chaudhri, DO Family Medicine Faculty Development Fellow, UPMC St Margaret March 5, 2016
Biosta's'cs Board Review Parul Chaudhri, DO Family Medicine Faculty Development Fellow, UPMC St Margaret March 5, 2016 Review key biosta's'cs concepts Understand 2 X 2 tables Objec'ves By the end of this
More informationAsthma self management. Duncan MacIntyre & Christine Bucknall August 2010
Asthma self management Duncan MacIntyre & Christine Bucknall August 2010 Health Belief Model These beliefs make it more likely that patients will follow preventive or therapeutic recommendations I am susceptible
More informationPLM Data Capabilities Overview June 2014
PLM Data Capabilities Overview June 2014 Our focus at PatientsLikeMe Help individual patients achieve better outcomes and live better, together Improve healthcare with real-world data that helps people
More informationJames H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
Disclosure Estrogen Therapy After Postmenopausal Hysterectomy: Issues, Challenges, Risks/Benefits James H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
More informationShared Decision Making in Diabetes: What, Why, and How? Nilay D. Shah Mayo Clinic Rochester, Minnesota, USA
Shared Decision Making in Diabetes: What, Why, and How? Nilay D. Shah Mayo Clinic Rochester, Minnesota, USA Disclosures Funding provided by: AHRQ: R18 HS019214; R18 HS018339 NIDDK: R34 DK84009 Foundation
More informationPredicting, Preventing and Managing Asthma Exacerbations. Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa
Predicting, Preventing and Managing Asthma Exacerbations Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa Asthma exacerbations Predicting exacerbation recognising
More informationBeyond Controlling for Confounding: Design Strategies to Avoid Selection Bias and Improve Efficiency in Observational Studies
September 27, 2018 Beyond Controlling for Confounding: Design Strategies to Avoid Selection Bias and Improve Efficiency in Observational Studies A Case Study of Screening Colonoscopy Our Team Xabier Garcia
More informationNew TLD Indication: Asthma RELIEF-1 Study. Nick ten Hacken, MD Study Co-Principal Investigator
New TLD Indication: Asthma RELIEF-1 Study Nick ten Hacken, MD Study Co-Principal Investigator The Burden of Asthma WW Adult Asthma Prevalence 230.5 Million Mild/Intermittent 161.9 Million (70%) Moderate
More informationInformation for Patients. Inhaler devices for routine treatment of chronic asthma in older children (aged 5-15 years)
Information for Patients Inhaler devices for routine treatment of chronic asthma in older children (aged 5-15 years) March 2002 Further information Further information on NICE and the full guidance on
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationASTRAZENECA v GLAXOSMITHKLINE
CASE AUTH/1986/4/07 ASTRAZENECA v GLAXOSMITHKLINE Symbicort and Seretide cost comparisons AstraZeneca complained about cost comparisons made by GlaxoSmithKline between AstraZeneca s Symbicort (budesonide/formoterol)
More informationCynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters
Cynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters Disclosures Speakers bureau of Novartis and Genentech
More informationBenefit/Risk Assessment A Critical Need
Benefit/Risk Assessment A Critical Need Christy Chuang-Stein, PhD Statistics, Pfizer Inc Society for Clinical Trials 30 th Annual Meeting 1 Some Basic Facts All pharmaceutical products have side effects
More informationShared Decision Making and Minimally Disruptive Medicine
Shared Decision Making and Minimally Disruptive Medicine Ian Hargraves JP Brito KER UNIT Center for Clinical and Translational Sciences Mayo Clinic Minimally Disruptive Medicine Effective Care that Fits
More information3/31/2015. Designing Clinical Research Studies: So You Want to Be an
Designing Clinical Research Studies: So You Want to Be an Inves@gator Andrea Bonny, MD Ellen Lançon Connor, MD On behalf Of The NASPAG Research CommiPee Objec@ves Learn to design a clinical research project
More informationPlacebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
More informationHarnessing health data for patient and public benefit. Pragmatic trials. Tjeerd van Staa University of Manchester
Harnessing health data for patient and public benefit Pragmatic trials Tjeerd van Staa University of Manchester Disclosures My department has received funding from GSK (sponsor of Salford Lung Study) for
More informationClinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis
Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine Achieving
More informationSAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) JUNE 2018
SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) JUNE 2018 SAFE HARBOR STATEMENT Savara Inc. ( Savara or the Company ) cau7ons you that statements in this presenta7on that are not a descrip7on of historical
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationLead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For
More informationPCRS-UK briefing document Asthma guidelines. November 2017
PCRS-UK briefing document Asthma guidelines November 2017 1 1. Background The Scottish Intercollegiate Guidelines Network (SIGN) and British Thoracic Society (BTS) have been collaborating on producing
More informationUnderstanding. Design & Sta/s/cs. in Clinical Trials
Understanding Design & Sta/s/cs in Clinical Trials 1 Why bother? 2 Experience- Based Medicine? Benjamin Rush Father of American Psychiatry 3 Experience- Based Medicine? Supported blood- lejng as treatment
More informationPulmonary Year in Review
Pulmonary Year in Review Rachel Givelber, MD University of Pittsburgh SOM Pulmonary, Allergy, Critical Care and Sleep Medicine Rachel Givelber, MD Assistant Professor of Medicine PACCM, UPSOM Disclosures
More informationReal-world data in pragmatic trials
Real-world data in pragmatic trials Harold C. Sox,MD The Patient-Centered Outcomes Research Institute Washington, DC Presenter Disclosure Information In compliance with the accrediting board policies,
More informationGuidelines for using the Voils two-part measure of medication nonadherence
Guidelines for using the Voils two-part measure of medication nonadherence Part 1: Extent of nonadherence (3 items) The items in the Extent scale are worded generally enough to apply across different research
More informationChoose a fertility clinic: update
Choose a fertility clinic: update Strategic delivery: Setting standards Increasing and informing choice Demonstrating efficiency economy and value Details: Meeting Authority Agenda item 10 Paper number
More informationStatistical Methods in Medical Research
Department of Statistics Western Michigan University Outline Surveys of Methodology 1 Survey of statistical methodology 2 Survey of contradicted studies 3 Threats to correct outcomes 1979 Methods Survey
More informationEngage and Empower Pa.ents with Interac.ve Technology. Northeast NAHAM Regional Conference Pa.ent Access: GeBng It Right Upfront October 22-23, 2012
Engage and Empower Pa.ents with Interac.ve Technology Northeast NAHAM Regional Conference Pa.ent Access: GeBng It Right Upfront October 22-23, 2012 NAHAM - Pa.ent Access Services 2 Pa%ent Access Services
More informationEasyRead guide to the PowerPoint slides. This is an EasyRead guide to the slides you will see on the screen.
EasyRead guide to the PowerPoint slides This is an EasyRead guide to the slides you will see on the screen. It has the slide you will see on the screen at the top of the page and an EasyRead of what it
More informationIMPROVING GLOBAL ESTIMATES: PROCESS AND MILESTONES IATT Webinar June 7 th 2016
Where did we start? Where did we get to? Where do we want to go? IMPROVING GLOBAL ESTIMATES: PROCESS AND MILESTONES IATT Webinar June 7 th 2016 Mar6na Penazzato Paediatric advisor HIV Department WHO, Geneva-
More informationPostmenopausal hormone therapy - cardiac disease risks and benefits
Postmenopausal hormone therapy - cardiac disease risks and benefits Tomi S. Mikkola, MD Helsinki University Central Hospital Department of Obstetrics and Gynecology Helsinki, Finland Disclosures Speaker/consulting
More informationStep up if needed (first, check adherence, environmental control and comorbid conditions) Patients ASSESS CONTROL. Step down if possible
12/9/212 Pharmacogenomics Treating the Individual Asthma Patient Elliot Israel, M.D. Professor of Medicine Harvard Medical School Brigham & Women s Hospital Partners Asthma Center Too much of a good thing?
More informationAsthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches
Asthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches William W. Busse,, M.D. University of Wisconsin School of Medicine and Public Health Madison, WI, USA Disclosure Slide Employment
More informationFinding Research Questions: Look at Both the New and the Old. September 23, 2016 Josie Briggs MD NIA Aging Research for the Specialties
Finding Research Questions: Look at Both the New and the Old September 23, 2016 Josie Briggs MD NIA Aging Research for the Specialties Quirky Ideas From Outside the Mainstream Physical resistance training
More informationEBM: Therapy. Thunyarat Anothaisintawee, M.D., Ph.D. Department of Family Medicine, Ramathibodi Hospital, Mahidol University
EBM: Therapy Thunyarat Anothaisintawee, M.D., Ph.D. Department of Family Medicine, Ramathibodi Hospital, Mahidol University How to appraise therapy literature Are the result valid? What are the result?
More informationMenopause management NICE Implementation
Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not
More informationModule 5. The Epidemiological Basis of Randomised Controlled Trials. Landon Myer School of Public Health & Family Medicine, University of Cape Town
Module 5 The Epidemiological Basis of Randomised Controlled Trials Landon Myer School of Public Health & Family Medicine, University of Cape Town Introduction The Randomised Controlled Trial (RCT) is the
More informationMisperceptions still exist that cardiovascular disease is not a real problem for women.
Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees
More informationTREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN. Dr Lại Lê Hưng Respiratory Department
TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN Dr Lại Lê Hưng Respiratory Department Literature review current through: Feb 2013. This topic last updated: Aug 14, 2012 INTRODUCTION Wheezing
More informationChapter 6. Experimental Studies
Chapter 6 Experimental Studies 1 Chapter 6 Outline 6.1 Introduction 6.2 Historical perspective 6.3 General concepts 6.4 Data analysis 2 Epi Experiments ( Trials ) Trials - from the French trier (to try)
More informationThe clinical effectiveness and costeffectiveness. treatment of chronic asthma in children under the age of 12 years
The clinical effectiveness and costeffectiveness of corticosteroids for the treatment of chronic asthma in children under the age of 12 years Submission of evidence from AstraZeneca UK Ltd regarding the
More informationSponsor. Generic drug name. Trial indication(s) Protocol number. Protocol title. Clinical trial phase. Study Start/End Dates.
Sponsor Novartis Generic drug name Fluticasone propionate Trial indication(s) Moderate-severe bronchial asthma Protocol number CQAE397A2202 Protocol title A randomized open label study to assess the utility
More informationImproving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
More informationApril 10 th, Bond Street, Toronto ON, M5B 1W8
Comprehensive Research Plan: Inhaled long-acting muscarinic antagonists (LAMAs; long-acting anticholinergics) for the treatment of chronic obstructive pulmonary disease (COPD) April 10 th, 2014 30 Bond
More informationIntegrated Mindfulness Interven1on
Integrated Mindfulness Interven1on Elizabeth Berlasso, NSRCT, Psychotherapist Rob Dickson, Clinical Team Leader Tara Sampalli, PhD, Manager Minakshi Dhir, Research Associate Integrated Chronic Care Service,
More informationsupport support support STAND BY ENCOURAGE AFFIRM STRENGTHEN PROMOTE JOIN IN SOLIDARITY Phase 3 ASSIST of the SASA! Community Mobilization Approach
support support support Phase 3 of the SASA! Community Mobilization Approach STAND BY STRENGTHEN ENCOURAGE PROMOTE ASSIST AFFIRM JOIN IN SOLIDARITY support_ts.indd 1 11/6/08 6:55:34 PM support Phase 3
More informationA Trial Implementa.on of a High Density Health Informa.on Exchange Standard: Are We Ready for Coordinated Care in High Impact Condi.ons?
A Trial Implementa.on of a High Density Health Informa.on Exchange Standard: Are We Ready for Coordinated Care in High Impact Condi.ons? Michael Hogarth, MD, FACP CMIO, Athena Breast Health Network Professor,
More informationTackling Tobacco Through Re-engineered Primary Care
2/27/18 Tackling Tobacco Through Re-engineered Primary Care Daren Wu, M.D. Chief Medical Officer Learning Objec>ves Understand the key stumbling blocks that can interfere with tobacco screening and treatment,
More informationBecause the more you know, the better you ll feel.
ABOUT ASTHMA Because the more you know, the better you ll feel. This booklet is designed to help you understand asthma and the things you can do every day to help control symptoms. As always, talk to your
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018
Breathtaking science Developing respiratory drugs to improve health and quality of life H.C. Wainwright Global Life Sciences Conference April 2018 www.veronapharma.com Forward-Looking Statements This presentation
More informationCaller: With regard to assessing asthma control, is there a benefit to using the ACQ over the ACT or vice versa?
Dr. Colice: Hello. I m Dr. Gene Colice, an adult pulmonologist and Professor of Medicine at the George Washington University School of Medicine in Washington, D.C. Joining me today is Dr. Anne Fuhlbrigge,
More informationomalizumab 150mg powder and solvent for injection (Xolair ) No. (259/06) Novartis Pharmaceuticals UK Ltd.
Scottish Medicines Consortium Re-Submission omalizumab 150mg powder and solvent for injection (Xolair ) No. (259/06) Novartis Pharmaceuticals UK Ltd. 8 December 2006 The Scottish Medicines Consortium (SMC)
More informationMedicines in Scotland: What s the right treatment for me? Information for patients and the public
Medicines in Scotland: What s the right treatment for me? Information for patients and the public You can read and download this document from our website. We are happy to consider requests for other languages
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2016?
Global Initiative for Asthma (GINA) What s new in GINA 2016? GINA Global Strategy for Asthma Management and Prevention GINA: A Brief History Established in 1993 Collaboration between NHLBI and WHO Multiple
More informationGenetic Tests and Genetic Counseling How to Analyze Your Own Genome
Genetic Tests and Genetic Counseling 02-223 How to Analyze Your Own Genome Genetic Tests for Huntington Disease Hun7ngton Disease Incurable brain disorder that runs in families Movement, cogni7ve, and
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationUse of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases
open access Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the and databases Yana Vinogradova, Carol Coupland, Julia Hippisley-Cox Division of
More informationAllwin Mercer Dr Andrew Zurek
Allwin Mercer Dr Andrew Zurek 1 in 11 people are currently receiving treatment for asthma (5.4 million people in the UK) Every 10 seconds, someone is having a potentially life-threatening asthma attack
More informationRespiratory Subcommittee of PTAC meeting held 5 February (minutes for web publishing)
Respiratory Subcommittee of PTAC meeting held 5 February 2010 (minutes for web publishing) Respiratory Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationModel based longitudinal metaanalysis of FEV1 in COPD trials A tool for efficacy benchmarking
Model based longitudinal metaanalysis of FEV1 in COPD trials A tool for efficacy benchmarking Julia Korell (1), Steven W. Martin (2), Mats O. Karlsson (1), Jakob Ribbing (1,3) (1) Uppsala University, Sweden
More informationComprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma
Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma Pharmacoepidemiology Unit July 10, 2014 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca
More informationLia Hotchkiss: I'm Lia Hotchkiss and I'm with the Agency for Healthcare. Research and Quality. We are one of the 12 agencies part of the Department of
Lia Hotchkiss, MPH, PMP, Comparative Effectiveness Research, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality (AHRQ), Rockville, MD Lia Hotchkiss: I'm Lia Hotchkiss and I'm
More information